Small Molecules Targeting Defective RNAs Show Therapeutic Potential in Prostate Cancer

Small Molecules Targeting Defective RNAs Show Therapeutic Potential in Prostate Cancer
Scientists at Florida’s Scripps Research Institute have developed a new drug candidate targeting prostate cancer, highlighting the therapeutic potential of a new class of drugs called small molecule RNA inhibitors. The study, “Defining RNA–Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor of an Oncogenic Noncoding RNA,” appeared in the journal ACS Central Science. “This is like

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *